- Obesity drug beloranib shows promise in Prader-Willi population in Phase 2 trials
- Study: Whooping cough vaccine may not prevent infection
- Mintel: Energy drink category up despite health concerns
- MarketsandMarkets projects the nutraceutical ingredient market to reach $33.6 billion by 2018
- Reports: Bill to extend federal regulations for compounding pharmacies expected to pass House, Senate
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for obesity in adults, the agency said Wednesday.
The FDA announced the approval of Arena Pharmaceuticals' Belviq (lorcaserin hydrochloride), designed for use alongside reduced-calorie diets and exercise, for chronic weight management. Eisai will distribute the drug.
"Obesity threatens the overall well-being of patients and is a major public health concern," FDA Center for Drug Evaluation and Research director Janet Woodcock said. "The approval of this drug, used responsibly in combination with a healthy diet and lifestyle, provides a treatment option for Americans who are obese or are overweight and have at least one weight-related comorbid condition."
The drug works by activating the brain's serotinin 2C receptor, which is believed to help people eat less and feel full after eating smaller amounts of food.